Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul 24;12(8):513-26.
doi: 10.1038/nrc3317.

Pushing the limits of targeted therapy in chronic myeloid leukaemia

Thomas O'Hare  1 , Matthew S Zabriskie, Anna M Eiring, Michael W Deininger
Affiliations
Review

Pushing the limits of targeted therapy in chronic myeloid leukaemia

Thomas O'Hare et al. Nat Rev Cancer. .

Erratum in

  • Nat Rev Cancer. 2012 Dec;12(12):886

Abstract

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual disease (MRD) is thought to reside in TKI-insensitive leukaemia stem cells (LSCs) that are not fully addicted to BCR-ABL1. Recent conceptual advances in both CML biology and therapeutic intervention have increased the potential for the elimination of CML cells, including LSCs, through simultaneous inhibition of BCR-ABL1 and other newly identified, crucial targets.

Trial registration: ClinicalTrials.gov NCT00574873 NCT00827138 NCT01207440.

PubMed Disclaimer

References

    1. Chem Biol Drug Des. 2011 Jan;77(1):1-11 - PubMed
    1. J Biol Chem. 1994 Sep 16;269(37):22925-8 - PubMed
    1. Science. 2000 Sep 15;289(5486):1938-42 - PubMed
    1. Blood. 2011 Dec 15;118(25):6521-8 - PubMed
    1. Blood. 2012 Mar 8;119(10):2335-45 - PubMed

MeSH terms

Substances

Associated data